Ginkgo Bioworks
DNA
342 hedge funds and large institutions have $2.14B invested in Ginkgo Bioworks in 2023 Q4 according to their latest regulatory filings, with 44 funds opening new positions, 109 increasing their positions, 98 reducing their positions, and 47 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
11% more repeat investments, than reductions
Existing positions increased: 109 | Existing positions reduced: 98
0.02% more ownership
Funds ownership: 1.94% → 1.95% (+0.02%)
5% less capital invested
Capital invested by funds: $2.25B → $2.14B (-$106M)
6% less first-time investments, than exits
New positions opened: 44 | Existing positions closed: 47
2% less funds holding
Funds holding: 348 → 342 (-6)
20% less call options, than puts
Call options by funds: $6.11M | Put options by funds: $7.6M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$25.1M |
| 2 |
State Street
Boston,
Massachusetts
|
+$5.51M |
| 3 |
VAS
Vestmark Advisory Solutions
Wakefield,
Massachusetts
|
+$4.57M |
| 4 |
EAM
Erste Asset Management
Vienna,
Austria
|
+$3.66M |
| 5 |
LIM
Lingotto Investment Management
London,
United Kingdom
|
+$3.37M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Schroder Investment Management Group
London,
United Kingdom
|
-$13.4M |
| 2 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$3.85M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$3.72M |
| 4 |
BHCM
Boulder Hill Capital Management
New York
|
-$2.65M |
| 5 |
HF
HRT Financial
New York
|
-$2.23M |
DNA Hedge Fund Activity: Q4 2023 in Review
342 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Ginkgo Bioworks (DNA) for Q4 2023, worth a combined $2.14B — down 4.7% from $2.25B a quarter earlier.
Sellers outnumbered buyers: 47 funds closed out of DNA and 44 opened new positions — a net loss of 3 holders — while 98 trimmed existing stakes and 109 added.
The largest buyer was ARK Investment Management, adding an estimated $25.1M. The largest seller was Schroder Investment Management Group, exiting entirely with an estimated $13.4M sold.
- 342 institutional investors held Ginkgo Bioworks (DNA) as of Q4 2023, down from 348 in Q3 2023.
- Funds reported $2.14B of Ginkgo Bioworks stock for Q4 2023, down 4.7% quarter-over-quarter.
- 44 funds opened new Ginkgo Bioworks positions in Q4 2023 and 47 closed out, a net change of -3 holders.
- The largest Ginkgo Bioworks buyer in Q4 2023 was ARK Investment Management, an estimated $25.1M added.
- The largest Ginkgo Bioworks seller in Q4 2023 was Schroder Investment Management Group, an estimated $13.4M sold.
Based on aggregated 13F filings for Q4 2023.